Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    3317828 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
Condition: B Cell Lymphoma
Intervention: Drug: IgG-RFB4-SMPT-dgA

Study has passed its completion date and status has not been verified in more than two years.